CIK medium
A culture medium and basal medium technology, applied in the direction of cell culture active agent, culture process, tissue culture, etc., can solve the problems of unsatisfactory number of CIK cells, poor activity and proliferation ability of CIK cells, etc., to improve activity and proliferation ability , Avoid reducing the concentration too fast, and enhance the effect of cross-linking
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Example Embodiment
[0031] Example 1
[0032] This embodiment provides a CIK cell culture medium. The CIK cell culture medium includes DMEM medium and additives added to the DMEM medium. In terms of the final concentration, the additives include the following components: polylysine Acid 25μg / mL, BCG polysaccharide nucleic acid 10mg / mL, sodium selenite 0.035μmol / mL, 4-hydroxyethylpiperazine ethanesulfonic acid 6μg / mL, reduced glutathione 3μg / L, adenosine Aminase 9μg / mL, IFN-γ sustained-release microspheres 2.5mg / mL, IL-2 sustained-release microspheres 1.75mg / mL, autologous plasma 5mL / L.
[0033] Preferably, the preparation method of the IL-2 sustained-release microspheres includes the following steps:
[0034] A. Add IL-2 and polyethylene glycol into the aqueous solution pre-added with mannitol and zinc sulfate, and stir evenly to obtain mixture A. The concentration of IL-2 in said mixture A is 2wt%, The concentration is 9wt%; the concentration of mannitol is 3wt%, and the concentration of zinc carbona...
Example Embodiment
[0054] Example 2
[0055] This embodiment provides a CIK cell culture medium. The CIK cell culture medium includes a basal culture medium and additives added to the basal culture medium. In terms of final concentration, the additives include the following components: polylysine Acid 20μg / mL, BCG polysaccharide nucleic acid 15mg / mL, sodium selenite 0.03μmol / mL, 4-hydroxyethylpiperazine ethanesulfonic acid 8μg / mL, reduced glutathione 2μg / L, adenosine Aminase 12µg / mL, IFN-γ sustained-release microspheres 2mg / mL, IL-2 sustained-release microspheres 2mg / mL, autologous plasma 4mL / L.
[0056] Preferably, the preparation method of the IL-2 sustained-release microspheres includes the following steps:
[0057] A. Add IL-2 and polyethylene glycol into the aqueous solution pre-added with mannitol and zinc sulfate, and stir evenly to obtain mixture A. The concentration of IL-2 in the mixture A is 1.2 wt%, and the polyethylene glycol The concentration is 12 wt%;
[0058] B. Add polyglycolic acid-...
Example Embodiment
[0078] Example 3
[0079] This embodiment provides a CIK cell culture medium. The CIK cell culture medium includes DMEM medium and additives added to the basal medium. In terms of the final concentration, the additives include the following components: polylysine Acid 30μg / mL, BCG polysaccharide nucleic acid 5mg / mL, sodium selenite 0.04μmol / mL, 4-hydroxyethylpiperazine ethanesulfonic acid 5μg / mL, reduced glutathione 4μg / L, adenosine Aminase 8µg / mL, IFN-γ sustained-release microspheres 3mg / mL, IL-2 sustained-release microspheres 1.5mg / mL, autologous plasma 6mL / L.
[0080] Preferably, the preparation method of the IL-2 sustained-release microspheres includes the following steps:
[0081] A. Add IL-2 and polyethylene glycol to the aqueous solution pre-added with mannitol and zinc sulfate, and stir evenly to obtain a mixture A. The concentration of IL-2 in the mixture A is 2.5 wt%, and the polyethylene glycol The concentration is 7wt%;
[0082] B. Add polyglycolic acid-polylactic acid-p...
PUM
Property | Measurement | Unit |
---|---|---|
Particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap